Literature DB >> 7707496

Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus.

J E Clements1, R C Montelaro, M C Zink, A M Amedee, S Miller, A M Trichel, B Jagerski, D Hauer, L N Martin, R P Bohm.   

Abstract

The simian immunodeficiency virus (SIV) macaque model of AIDS has provided a valuable system with which to investigate vaccine approaches for protection against human immunodeficiency virus type 1 (HIV-1) infection. In particular, the ability of macaques persistently infected with attenuated infectious molecular clones of SIV to resist challenge with the pathogenic parental swarm has conclusively demonstrated that protective immunity can be achieved by immunization prior to exposure. The breadth of these protective responses and the immunological correlates of protection, however, have not been identified. In addition, vaccine studies have mainly employed lymphocyte-tropic strains of HIV-1 and SIV. Recent studies have implicated macrophage-tropic strains in the transmission of HIV-1 and have suggested that these virus strains should be examined in vaccine strategies. Macrophage-tropic viruses may confer additional advantages in the induction of protective immunity by replication in antigen-presenting cells. In this study, the immune response of rhesus macaques inoculated with an attenuated macrophage-tropic recombinant of SIVmac239 (SIV/17E-Cl) was evaluated with respect to protective immunity by heterologous challenge at various times after infection. Vigorous type-specific neutralizing-antibody responses restricted to SIV/17E-Cl were evident by 2 weeks postinfection. By 7 months, however, cross-reactive neutralizing antibodies emerged which neutralized not only SIV/17E-Cl but also the heterologous primary isolate SIV/DeltaB670. Challenge of SIV/17E-Cl-infected monkeys with SIV/DeltaB670 at various times postinfection demonstrated that protective responses were associated with the appearance of cross-reactive neutralizing antibodies. Furthermore, passive transfer of sera from SIV/17E-Cl-infected animals passively protected two of four naive recipients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7707496      PMCID: PMC188966     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Selection of genetic variants of simian immunodeficiency virus in persistently infected rhesus monkeys.

Authors:  D P Burns; R C Desrosiers
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

2.  Importance of the nef gene for maintenance of high virus loads and for development of AIDS.

Authors:  H W Kestler; D J Ringler; K Mori; D L Panicali; P K Sehgal; M D Daniel; R C Desrosiers
Journal:  Cell       Date:  1991-05-17       Impact factor: 41.582

Review 3.  Antibody affinity and protection in virus infections.

Authors:  A A Salmi
Journal:  Curr Opin Immunol       Date:  1991-08       Impact factor: 7.486

4.  The genetic fate of molecularly cloned simian immunodeficiency virus in experimentally infected macaques.

Authors:  P R Johnson; T E Hamm; S Goldstein; S Kitov; V M Hirsch
Journal:  Virology       Date:  1991-11       Impact factor: 3.616

5.  Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys.

Authors:  P Putkonen; R Thorstensson; L Ghavamzadeh; J Albert; K Hild; G Biberfeld; E Norrby
Journal:  Nature       Date:  1991-08-01       Impact factor: 49.962

6.  A novel enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies to HIV-1 envelope glycoproteins based on immobilization of viral glycoproteins in microtiter wells coated with concanavalin A.

Authors:  J E Robinson; D Holton; J Liu; H McMurdo; A Murciano; R Gohd
Journal:  J Immunol Methods       Date:  1990-08-28       Impact factor: 2.303

7.  Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120.

Authors:  K S Steimer; C J Scandella; P V Skiles; N L Haigwood
Journal:  Science       Date:  1991-10-04       Impact factor: 47.728

8.  Lack of HIV-1 V3 region sequence diversity in two haemophiliac patients infected with a putative biologic clone of HIV-1.

Authors:  K Cichutek; S Norley; R Linde; W Kreuz; M Gahr; J Löwer; G von Wangenheim; R Kurth
Journal:  AIDS       Date:  1991-10       Impact factor: 4.177

9.  Identification of viral determinants of macrophage tropism for simian immunodeficiency virus SIVmac.

Authors:  B Banapour; M L Marthas; R A Ramos; B L Lohman; R E Unger; M B Gardner; N C Pedersen; P A Luciw
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

10.  Macrophage-tropic variants of SIV are associated with specific AIDS-related lesions but are not essential for the development of AIDS.

Authors:  R C Desrosiers; A Hansen-Moosa; K Mori; D P Bouvier; N W King; M D Daniel; D J Ringler
Journal:  Am J Pathol       Date:  1991-07       Impact factor: 4.307

View more
  62 in total

1.  Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus.

Authors:  S A Hammond; F Li; B M McKeon; S J Cook; C J Issel; R C Montelaro
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Immunization with a live, attenuated simian immunodeficiency virus vaccine leads to restriction of viral diversity in Rhesus macaques not protected from pathogenic challenge.

Authors:  D L Sodora; K E Sheridan; P A Marx; R I Connor
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

3.  Characterization of a macaque recombinant monoclonal antibody that binds to a CD4-induced epitope and neutralizes simian immunodeficiency virus.

Authors:  J Glamann; V M Hirsch
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

4.  A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.

Authors:  F Verrier; S Burda; R Belshe; A M Duliege; J L Excler; M Klein; S Zolla-Pazner
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

5.  Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus.

Authors:  R Shibata; C Siemon; S C Czajak; R C Desrosiers; M A Martin
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

6.  Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus.

Authors:  R P Johnson; R L Glickman; J Q Yang; A Kaur; J T Dion; M J Mulligan; R C Desrosiers
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

7.  Cell tropism of simian immunodeficiency virus in culture is not predictive of in vivo tropism or pathogenesis.

Authors:  Juan T Borda; Xavier Alvarez; Ivanela Kondova; Pyone Aye; Meredith A Simon; Ronald C Desrosiers; Andrew A Lackner
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

8.  A single amino acid change and truncated TM are sufficient for simian immunodeficiency virus to enter cells using CCR5 in a CD4-independent pathway.

Authors:  A Bonavia; B T Bullock; K M Gisselman; B J Margulies; J E Clements
Journal:  Virology       Date:  2005-10-10       Impact factor: 3.616

9.  Simian immunodeficiency virus DNA vaccine trial in macaques.

Authors:  S Lu; J Arthos; D C Montefiori; Y Yasutomi; K Manson; F Mustafa; E Johnson; J C Santoro; J Wissink; J I Mullins; J R Haynes; N L Letvin; M Wyand; H L Robinson
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

Review 10.  Viral sequence diversity: challenges for AIDS vaccine designs.

Authors:  Sean P McBurney; Ted M Ross
Journal:  Expert Rev Vaccines       Date:  2008-11       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.